We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Medix Biochemica Launches Refreshed and Expanding Brand to Reflect Growing IVD Products Portfolio

By LabMedica International staff writers
Posted on 04 Mar 2022

Medix Biochemica (Finland) is launching a rejuvenated brand to reflect both the improvements to its offering as a result of recent acquisitions, and its ongoing commitment to the in vitro diagnostics (IVD) industry. The company hopes that its accelerated growth will establish its status as the ultimate IVD raw materials supplier. A new website brings to life a brand-new creative campaign that communicates every aspect of Medix’s expertise – alongside an aspirational corporate identity to reflect the company’s ambitions.

In line with its commitment to offering its customers the most comprehensive IVD raw materials portfolio in the business, Medix has acquired several companies, each with their own expertise across the IVD market. In 2019, Lee Biosolutions was acquired, followed by EastCoast Bio and Biostride in 2020, Diaclone just last year and, most recently, myPOLS Biotec GmbH, which will strengthen its existing molecular diagnostics division, MedixMDx. This integration has helped Medix broaden its portfolio to over 5,000 products in categories such as molecular reagents, enzymes, biospecimens and immunoreagents.


Image: Medix Biochemica introduces its refreshed and expanding brand (Photo courtesy of Medix Biochemica)
Image: Medix Biochemica introduces its refreshed and expanding brand (Photo courtesy of Medix Biochemica)

Based on customer feedback and its aim to create a better business for its customers, has launched brand new website that will be the go-to place for its customers. Whether it’s a streamlined product experience or a specific service such as antibody, DNA or RNA polymerase engineering, customers will be able to find out more and contact the company directly to discuss their needs. The launch is another step towards Medix’s vision to be the first-choice, independent raw material partner for the IVD industry.

“The launch of the new Medix Biochemica brand is the culmination of years of hard work,” said Steve Ferguson, CEO of Medix Biochemica. “We are so excited to be able to offer our customers more services, more expertise, more product choices than ever before. And most importantly, still with the same quality and care our customers are used to receiving from Medix Biochemica.”

Related Links:
Medix Biochemica


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Online QC Software
Acusera 24•7
New
Steam Sterilizer
Hi Vac II Line
New
Automated Clinical Chemistry Analyzer
Envoy 500+

Latest Industry News

Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
04 Mar 2022  |   Industry

FDA Clears Blood-Based Companion Diagnostic for Advanced Breast Cancer Therapy
04 Mar 2022  |   Industry

CareDx Expands Precision Oncology Portfolio with Naveris Acquisition
04 Mar 2022  |   Industry



ADLM